Express Scripts Further Advances Transparency and Affordability for Consumers and Clients
Express Scripts, the pharmacy benefits management business of Evernorth, a subsidiary of The Cigna Group (NYSE: CI), today announced several actions to further evolve its pharmacy benefit management (PBM) model. The new solutions and capabilities will increase access to affordable…
UnitedHealthcare Provides $275,000 to Three North Carolina Nonprofits To Improve Health Outcomes for Children
UnitedHealthcare Community Plan of North Carolina has announced $275,000 in grant funding to three local organizations supporting children in kinship and foster care across the state. “Caring for the most vulnerable members of our community starts with meeting their most…
Interested in our Q1 financial results?
Today, Boston Scientific shared its financial results for the first quarter of 2023. Overall, we generated net sales of $3.389 billion during the first quarter of 2023, growing 14 percent on an organic[1] basis compared to the prior year period. We…
Four things to know about our acquisition of Apollo Endosurgery
Mike Jones just celebrated his 28th year at Boston Scientific. Now a senior vice president at the company, he’s also the president of the Endoscopy business – which means he knows great innovation in the field when he sees it. …
A sense of belonging and purpose
May is Asian American and Pacific Islander Heritage Month, and this year’s theme is “Advancing Leaders Through Opportunity.” Hear from two Boston Scientific employees about how their involvement in the Pacific East Asian Resources in Leadership (PEARL) employee resource group…
Boston Scientific Announces Results for First Quarter 2023
Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.389 billion during the first quarter of 2023, growing 12.0 percent on a reported basis, 14.9 percent on an operational1 basis and 14.0 percent on an organic2 basis, all compared to the prior year period.…
DANAHER REPORTS FIRST QUARTER 2023 RESULTS
Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders. For the quarter ended March 31, 2023 net earnings were $1.4 billion, or $1.94 per diluted common share and non-GAAP adjusted…
CVS Health reports first quarter results, completes acquisitions of Signify Health and Oak Street Health
CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended March 31, 2023. Key financial data First quarter highlights Note: Financial information for the three months ended March 31, 2022 throughout this press release has been revised…
4 Expert Ways to Fight ‘Depression Fatigue’
If you have depression, you’ve probably experienced feeling so sluggish that even tiny tasks like washing your face seem insurmountable. This feeling — commonly known as “depression fatigue” — is more than mere tiredness. “It is not the same feeling you…
Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines
Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that it has signed a distribution and collaboration agreement with Adalvo for exclusive Sandoz rights to commercialize six products in the US across key therapeutic areas, including antifungal/antibiotic, oncology…
Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion and recommended granting a marketing authorization for Cosentyx® (secukinumab) in adults with active moderate to severe hidradenitis suppurativa…
Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
Novartis will present new data from its oncology portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, including advancements in breast cancer, prostate cancer and lung cancer from more than 40 Novartis-sponsored and investigator-led trials. Primary results…